Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive SEP-363856 (Ulotaront) in Adults with Major Depressive Disorder
2022-500538-27-00Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Ulotaront adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change in MADRS total score from end of Phase A (Week 8) to end of Phase B (Week 14). Started Mar 2023; status: completed.
02
Drugs
ulotaront
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-500538-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500538-27-00.